Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445088 in adults with CIDP
2024-512345-16-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Sanofi. Primary endpoints: Part A, SOC-Treated: Percentage of participants relapsing after withdrawal of SOC and during the SAR445088 treatment period, Part A, SOC-Refractory (initial and low dose group) and SOC-Naïve: Percentage of participants responding during the SAR445088 treatment period and 1 more. Started Oct 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-512345-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512345-16-00.